Since recent studies suggest that a combination of beta amyloid and neuroinflammation is closely associated with AD progression, Stat4 may be a prime target for suppressing both of these HFD-C associated factors, and thus for treatment of AD. The gene discussed is STAT4; the disease is Alzheimer disease.